saxenda glp 1 agonist Article » ProAct Saxenda: A Breakthrough Weight Loss

Effect of Different Antidiabetic Medications on Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score among Patients with Type-2 Diabetes Mellitus: A Multicenter Non-Interventional Observational Study

The findings demonstrated a significant reduction in all-cause mortality, with an odds ratio of 0.49 (95% CI [0.410.60]

J Clin Gastroenterol

Glycaemic control may improve within the first few weeks, whilst significant weight-related energy benefits usually take 3-6 months to become apparent

On the basis of several putative modes of action under investigation (for example, neuroprotective and anti-inflammatory properties, regulation of reward pathways), there is an emerging consensus that GLP-1RAs could be repurposed for use in neuropsychiatric conditions 25,26,27,28,29,30,31,32